- Home
- IMMX vs ECOR Comparison
IMMX vs ECOR Comparison
Compare IMMX & ECOR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IMMX
- ECOR
- Stock Information
- Founded
- IMMX 2014
- ECOR 2005
- Country
- IMMX United States
- ECOR United States
- Employees
- IMMX N/A
- ECOR N/A
- Industry
- IMMX Medicinal Chemicals and Botanical Products
- ECOR Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Sector
- IMMX Health Care
- ECOR Health Care
- Exchange
- IMMX Nasdaq
- ECOR Nasdaq
- Market Cap
- IMMX 50.1M
- ECOR 40.1M
- IPO Year
- IMMX 2021
- ECOR 2018
- Fundamental
- Price
- IMMX $2.09
- ECOR $4.65
- Analyst Decision
- IMMX Strong Buy
- ECOR Strong Buy
- Analyst Count
- IMMX 1
- ECOR 2
- Target Price
- IMMX $7.00
- ECOR $25.50
- AVG Volume (30 Days)
- IMMX 59.6K
- ECOR 135.3K
- Earning Date
- IMMX 05-20-2025
- ECOR 05-07-2025
- Dividend Yield
- IMMX N/A
- ECOR N/A
- EPS Growth
- IMMX N/A
- ECOR N/A
- EPS
- IMMX N/A
- ECOR N/A
- Revenue
- IMMX N/A
- ECOR $26,458,000.00
- Revenue This Year
- IMMX N/A
- ECOR $32.20
- Revenue Next Year
- IMMX N/A
- ECOR $46.27
- P/E Ratio
- IMMX N/A
- ECOR N/A
- Revenue Growth
- IMMX N/A
- ECOR 41.54
- 52 Week Low
- IMMX $1.26
- ECOR $5.02
- 52 Week High
- IMMX $2.71
- ECOR $19.49
- Technical
- Relative Strength Index (RSI)
- IMMX 61.41
- ECOR 28.33
- Support Level
- IMMX $1.92
- ECOR $6.01
- Resistance Level
- IMMX $2.25
- ECOR $7.14
- Average True Range (ATR)
- IMMX 0.17
- ECOR 0.77
- MACD
- IMMX 0.03
- ECOR -0.05
- Stochastic Oscillator
- IMMX 67.61
- ECOR 0.51
About IMMX Immix Biopharma Inc.
Immix Biopharma Inc is engaged in the discovery and development of novel cell therapies for hematologic malignancies (blood cancers) and other indications. It is a clinical-stage biopharmaceutical company developing a novel class of Tissue-Specific Therapeutics TM in oncology and inflammation. Its TME Normalization Technology allows drug candidates to circulate in the bloodstream, exit through tumor blood vessels and simultaneously attack all components of the TME. Its product candidates include CAR-T NXC-201 for autoimmune diseases, and IMX-110 for treatment of soft tissue sarcoma.
About ECOR electroCore Inc.
electroCore Inc is a commercial stage bioelectronic medicine company with a platform for non-invasive vagus nerve stimulation therapy initially focused on neurology. The company's product gammaCore is Food and Drug Administration cleared in the United States for adjunctive use for the preventive treatment of cluster headache in adult patients, the acute treatment of pain associated with episodic cluster headache in adult patients, the acute treatment of pain associated with migraine headache in adult patients, and the prevention of migraine in adult patients, The use of gammaCore by adolescent patients and Treatment of hemicrania continua and paroxysmal hemicrania in adult patients.